登录 | 注册    关注公众号  
微信公众号
搜索
 > 【ALPL】

ALPL信息

英文名称:Alkaline phosphatase, tissue-nonspecific isozyme
中文名称:非组织特异性碱性磷酸酶
靶点别称:Alkaline Phosphatase, Biomineralization Associated,EC:3.1.3.1,Alkaline Phosphatase Liver/Bone/Kidney Isozyme,Liver/Bone/Kidney-Type Alkaline Phosphatase,ALPL,AP-TNAP,Alkaline Phosphatase, Liver/Bone/Kidney,Tissue Non-Specific Alkaline Phosphatase,TNSALP,Alkaline Phosphatase, Tissue-Nonspecific Isozyme,Tissue-Nonspecific ALP,EC 3.1.3.1,APTNAP,TNALP,TNAP,HOPS
上市药物数量:1
临床药物数量:3
最高研发阶段:批准上市

ALPL产品列表

ACRO质量管理体系
 
评论(0)
 

ALPL分子别名

AP-TNAP, APTNAP, HOPS, HPPA, HPPC, HPPI, HPPO, TNALP, TNAP, TNS-ALP, TNSALP

ALPL分子背景

This gene encodes a member of the alkaline phosphatase family of proteins. There are at least four distinct but related alkaline phosphatases: intestinal, placental, placental-like, and liver/bone/kidney (tissue non-specific). The first three are located together on chromosome 2, while the tissue non-specific form is located on chromosome 1. The product of this gene is a membrane bound glycosylated enzyme that is not expressed in any particular tissue and is, therefore, referred to as the tissue-nonspecific form of the enzyme. Alternative splicing results in multiple transcript variants, at least one of which encodes a preproprotein that is proteolytically processed to generate the mature enzyme. This enzyme may play a role in bone mineralization. Mutations in this gene have been linked to hypophosphatasia, a disorder that is characterized by hypercalcemia and skeletal defects.

ALPL上市药物信息

英文名称 中文名称 研发代码 研发阶段 公司 最早商品名 最早批准国家 最早适应症 最早批准公司 最早批准日期 适应症 临床试验
Asfotase alfa sTNALP-FcD10; ALXN-1215; sALP-FcD10; ENB-0040 批准上市 Alexion Pharmaceuticals Inc Strensiq Japan 低磷酸酯酶症 Alexion Pharmaceuticals Inc 2015-07-03 低磷酸酯酶症 详情

ALPL临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
ALXN-1850 ALXN-1850 临床三期 Alexion Pharmaceuticals Inc 低磷酸酯酶症 详情
DS-1211 DS-1211 临床二期 桑福德伯翰医学研究所, 第一三共株式会社 异位骨化, 弹性假黄瘤 详情
ALXN-1910 ALXN-1910 临床一期 Alexion Pharmaceuticals Inc 详情

消息提示

请输入您的联系方式,再点击提交!

确定